[Skip to Navigation]
Clinical Observation
Jan 9, 2012

The Effect of Herbal Medications on Thyroid Hormone Economy and Estrogen-Sensitive Hepatic Proteins in a Patient With Prostate Cancer

Author Affiliations

Author Affiliations: Brooke Army Medical Center, Fort Sam Houston, Texas (Dr Viswanathan); and Endocrinology Service, Walter Reed National Military Medical Center, Bethesda, Maryland (Dr Vigersky).

Arch Intern Med. 2012;172(1):58-60. doi:10.1001/archinternmed.2011.596

Nonprescription drugs such as PC-SPES (Botanic Lab) (PC, abbreviation for prostate cancer; SPES, Latin for hope)—an herbal therapy for prostate cancer—are part of the complementary and alternative medicine (CAM) approach to health. PC-SPES was removed from the US market in 2002 owing to contamination with indomethacin, diethylstilbestrol, and warfarin.1 Yet it and similar preparations remain widely used because they are available online. Their clinical effect on nonprostatic, hormonally responsive systems has not been studied.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    1 Comment for this article
    EXPAND ALL
    Inaccurate herbal product descriptions
    Wendy L. Applequist, PhD | Missouri Botanical Garden Send reply
    This article may lead to the impression that GCP and Zyflamend ("all of these products that affected his PSA...") contain saw palmetto and Panax pseudoginseng. The eTable intended to provide more accurate information contains inaccuracies, at least for Zyflamend. It states that Zyflamend contains the fungus Ganoderma lucidum; omits seven ingredients, including some (turmeric, ginger, green tea) with well-demonstrated anti-cancer activities; and lists marker compounds present in two listed botanicals (resveratrol and wogonin, of which only 0.08 mg is present) as if they were separately added ingredients. It also lists "rhizome" as a separate ingredient, whereas this term references a type of plant organ. Zyflamend is a mixture of anti-inflammatory botanicals that contains no species commonly used for prostate disorders, yet it has been reported to reduce PSA levels in about half of subjects at increased risk of prostate cancer (1). By contrast, saw palmetto, used alone, has repeatedly been reported not to affect PSA levels. It seems premature to conclude that saw palmetto and Panax pseudoginseng are "the 2 key components of PC-SPES" merely because one patient had modestly reduced PSA levels during a relatively brief period in which he took a product, PC Plus, that had only those two ingredients in common with PC-SPES. The evidence does indicate that one of those two plants is likely to be responsible for the other idiosyncratic metabolic effects (elevation of TSH, HDL-C, etc.) reported for this person. The probably more interesting question of which ingredients in the last-used combination of supplements are responsible for the very impressive long-term suppression of PSA levels has not been answered. (1) Capodice JL, Gorroochurn P, Cammack AS, et al. Zyflamend in men with high-grade prostatic intraepithelial neoplasia: results of a phase I clinical trial. J Soc Integr Oncol 2009;7(2):43-51.
    Conflict of Interest: None declared
    CONFLICT OF INTEREST: None Reported
    READ MORE
    ×